Go Pro
NASDAQ:PRFX

PainReform Q2 2025 Earnings Report

PainReform logo
$0.86 -0.07 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 +0.04 (+5.10%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform EPS Results

Actual EPS
-$2.73
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PainReform Earnings Headlines

PainReform Ltd. (NASDAQ:PRFX) Sees Significant Decrease in Short Interest
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX), a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

View PainReform Profile